[Skip to Content]
[Skip to Content Landing]
Views 450
Citations 0
Viewpoint
February 2018

Personalized Medicine and the Contradictions and Limits of First-Generation Deescalation Trials in Patients With Human Papillomavirus–Positive Oropharyngeal Cancer

Author Affiliations
  • 1Radiotherapy 2 Unit, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy
  • 2Medical Oncology 3 Department, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy
  • 3University of Milan, Italy
JAMA Otolaryngol Head Neck Surg. 2018;144(2):99-100. doi:10.1001/jamaoto.2017.2308

In recent years, the term “personalized medicine,” which indicates a treatment tailored for each individual patient, has been widely replaced by the term “precision medicine.” This latter, in a more accurate and broader way, associates patient’s care with genetic, environmental, clinical, and lifestyle factors. In the oncological community, precision medicine refers to genomics-driven cancer medicine.1

First Page Preview View Large
First page PDF preview
First page PDF preview
×